New hope for Tough-to-Treat myeloma: experimental drug SG2918 enters human trials

NCT ID NCT07454187

First seen Mar 11, 2026 · Last updated May 09, 2026 · Updated 8 times

Summary

This early-stage study tests a new drug called SG2918 in 40 people whose multiple myeloma has returned or not responded to prior treatments. The main goal is to check the drug's safety and how well the body tolerates it. Researchers will also measure how the drug moves through the body and look for early signs that it might help control the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Henan Cancer Hospital

    Zhengzhou, Henan, 450000, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • The First Affiliated Hospital Of Soochow University

    Suzhou, Jiangsu, 215006, China

    Contact Email: •••••@•••••

  • The Second Affiliated Hospital Of Xi an Jiaotong University (Xibei Hospital)

    Xi’an, Shanxi, 710000, China

    Contact Email: •••••@•••••

  • The Second Affiliated Hospital Zhejiang University School Of Medicine

    Hangzhou, Zhejiang, 310056, China

Conditions

Explore the condition pages connected to this study.